{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:45:39Z","timestamp":1785930339098,"version":"3.56.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"DOI":"10.1007\/s00408-026-00918-7","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:56:18Z","timestamp":1785923778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"204","author":[{"given":"Bingxue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranpu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"3","key":"918_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"918_CR2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/ijms26052049","volume":"26","author":"B Smolarz","year":"2025","unstructured":"Smolarz B, Lukasiewicz H, Samulak D, Piekarska E, Kolacinski R, Romanowicz H (2025) Lung Cancer-epidemiology, pathogenesis, treatment and molecular aspect (review of literature). Int J Mol Sci 26(5):2049","journal-title":"Int J Mol Sci"},{"key":"918_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810046","author":"L Liu","year":"2024","unstructured":"Liu L, Soler J, Reckamp KL, Sankar K (2024) Emerging targets in non-small cell lung cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms251810046","journal-title":"Int J Mol Sci"},{"issue":"14","key":"918_CR4","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","volume":"23","author":"PA J\u00e4nne","year":"2005","unstructured":"J\u00e4nne PA, Engelman JA, Johnson BE (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23(14):3227\u20133234","journal-title":"J Clin Oncol"},{"issue":"30","key":"918_CR5","doi-asserted-by":"publisher","first-page":"50209","DOI":"10.18632\/oncotarget.16854","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Wang P, Zhang C, Ma Z (2017) Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer. Oncotarget 8(30):50209\u201350220","journal-title":"Oncotarget"},{"issue":"6","key":"918_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A (2023) 20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight. Biochimica et Biophysica Acta (BBA)\u2013Rev Cancer 1878(6):188967","journal-title":"Biochimica et Biophysica Acta (BBA)\u2013Rev Cancer"},{"issue":"1","key":"918_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12943-023-01811-0","volume":"22","author":"K Li","year":"2023","unstructured":"Li K, Peng ZY, Wang R, Li X, Du N, Liu DP et al (2023) Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. Mol Cancer 22(1):103","journal-title":"Mol Cancer"},{"issue":"1","key":"918_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12916-022-02580-1","volume":"20","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li C, Wang Z, Wang Z, Wu R, Wu Y et al (2022) Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. BMC Med 20(1):426","journal-title":"BMC Med"},{"issue":"2","key":"918_CR9","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev 18(2):e1230","journal-title":"Campbell Syst Rev"},{"issue":"10","key":"918_CR10","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133","journal-title":"JBI Evid Synth"},{"issue":"26","key":"918_CR11","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.21.00276","volume":"39","author":"SI Rothschild","year":"2021","unstructured":"Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A et al (2021) SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol 39(26):2872\u20132880","journal-title":"J Clin Oncol"},{"issue":"29","key":"918_CR12","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/sim.4040","volume":"29","author":"T Stijnen","year":"2010","unstructured":"Stijnen T, Hamza TH, \u00d6zdemir P (2010) Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Statist Med 29(29):3046\u20133067","journal-title":"Statist Med"},{"issue":"2","key":"918_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s11606-021-07098-5","volume":"37","author":"L Lin","year":"2022","unstructured":"Lin L, Xu C, Chu H (2022) Empirical comparisons of 12 meta-analysis methods for synthesizing proportions of binary outcomes. J Gen Intern Med 37(2):308\u2013317","journal-title":"J Gen Intern Med"},{"issue":"1","key":"918_CR14","first-page":"13","volume":"6","author":"LK Siegel","year":"2025","unstructured":"Siegel LK, Silva M, Lin L, Chen Y, Liu Y-L, Chu H (2025) Choice of link functions for generalized linear mixed models in meta-analyses of proportions. Res Methods Med Health Sci 6(1):13\u201323","journal-title":"Res Methods Med Health Sci"},{"key":"918_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-analysis with R","author":"G Schwarzer","year":"2015","unstructured":"Schwarzer G, Carpenter JR, R\u00fccker G (2015) Meta-analysis with R. Springer International Publishing"},{"issue":"1","key":"918_CR16","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1038\/s41467-023-40349-z","volume":"14","author":"D Bian","year":"2023","unstructured":"Bian D, Sun L, Hu J, Duan L, Xia H, Zhu X et al (2023) Neoadjuvant afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study. Nat Commun 14(1):4655","journal-title":"Nat Commun"},{"issue":"7","key":"918_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/oncolo\/oyae107","volume":"29","author":"AEB Chang","year":"2024","unstructured":"Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J et al (2024) The ASCENT trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist 29(7):609\u2013618","journal-title":"Oncologist"},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","volume":"178","author":"C Lv","year":"2023","unstructured":"Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H et al (2023) Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer 178:151\u2013156","journal-title":"Lung Cancer"},{"key":"918_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00071","author":"CM Blakely","year":"2024","unstructured":"Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC et al (2024) Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.24.00071","journal-title":"J Clin Oncol"},{"issue":"2","key":"918_CR20","first-page":"157","volume":"24","author":"L Xiong","year":"2019","unstructured":"Xiong L, Li R, Sun J, Lou Y, Zhang W, Bai H et al (2019) Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm. Phase II Study Oncol 24(2):157-e64","journal-title":"Phase II Study Oncol"},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.lungcan.2016.11.022","volume":"104","author":"YL Wu","year":"2017","unstructured":"Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B et al (2017) Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin\/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung cancer (Amsterdam, Netherlands) 104:119\u201325","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"918_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx729.007","volume":"28","author":"J Vansteenkiste","year":"2017","unstructured":"Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Cobo Dols MA, Cho EK et al (2017) CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the FLAURA study. Ann Oncol 28:x189","journal-title":"Ann Oncol"},{"key":"918_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9005","author":"YL Wu","year":"2020","unstructured":"Wu YL, Zhong W, Wang Q, Mao W, Xu ST, Wu L et al (2020) CTONG1104: adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9005","journal-title":"J Clin Oncol"},{"issue":"10","key":"918_CR24","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J et al (2023) Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol 41(10):1830\u201340","journal-title":"J Clin Oncol"},{"key":"918_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8502","author":"YL Wu","year":"2021","unstructured":"Wu YL, Zhong W, Chen KN, Chen C, Yang F, Yang XN et al (2021) CTONG1103: final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8502","journal-title":"J Clin Oncol"},{"issue":"4","key":"918_CR26","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.3390\/ijms24044126","volume":"24","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Tan AC (2023) Unraveling the Impact of intratumoral heterogeneity on EGFR tyrosine K inase inhibitor resistance in EGFR-mutated NSCLC. Int J Mole Sci 24(4):4126","journal-title":"Int J Mole Sci"},{"issue":"5","key":"918_CR27","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3390\/cancers12051196","volume":"12","author":"MG Ferrara","year":"2020","unstructured":"Ferrara MG, Di Noia V, D\u2019Argento E, Vita E, Damiano P, Cannella A et al (2020) Oncogene-Addicted non-small-cell lung cancer: treatment opportunities and future perspectives. Cancers (Basel). 12(5):1196","journal-title":"Cancers (Basel)."},{"key":"918_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00165","volume":"5","author":"G Baronzio","year":"2015","unstructured":"Baronzio G, Parmar G, Baronzio M (2015) Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid. Front Oncol 5:165","journal-title":"Front Oncol"},{"issue":"1","key":"918_CR29","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1038\/s41598-022-10938-x","volume":"12","author":"C-H Lee","year":"2022","unstructured":"Lee C-H, Shen M-C, Tsai M-J, Chang J-S, Huang Y-B, Yang Y-H et al (2022) Proton pump inhibitors reduce the survival of advanced lung cancer pat ients with therapy of gefitinib or erlotinib. Sci Rep 12(1):7002","journal-title":"Sci Rep"},{"key":"918_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103162","volume":"148","author":"D Stylianakis","year":"2026","unstructured":"Stylianakis D, Bertaglia V, Sangiolo D, Podda M, Saba G, Stylianakis I et al (2026) The antibiotic-immunotherapy interaction in NSCLC: a systematic review and meta-analysis of 54,250 patients across three outcomes. Cancer Treat Rev 148:103162","journal-title":"Cancer Treat Rev"},{"key":"918_CR31","doi-asserted-by":"crossref","unstructured":"Herbst RS, Wu Y-L, John T, Grohe C, Majem M, Wang J, et al (2023) Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol 41(10):1830","DOI":"10.1200\/JCO.22.02186"},{"key":"918_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040585","author":"HF Hetta","year":"2025","unstructured":"Hetta HF, Aljohani HM, Sirag N, Elfadil H, Salama A, Al-Twalhy R et al (2025) Synergizing success: the role of anlotinib combinations in advanced non-small cell lung cancer treatment. Pharm (Basel). https:\/\/doi.org\/10.3390\/ph18040585","journal-title":"Pharm (Basel)"},{"issue":"5","key":"918_CR33","first-page":"652","volume":"18","author":"HF Hetta","year":"2025","unstructured":"Hetta HF, Alqifari SF, Alshehri K, Alhowiti A, Alharbi SS, Mirghani H et al (2025) Efficacy of anlotinib plus docetaxel in advanced NSCLC previously treated with platinum-based chemotherapy: a systematic review and meta-analysis. Pharm (Basel). 18(5):652","journal-title":"Pharm (Basel)."},{"issue":"22","key":"918_CR34","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","volume":"30","author":"EE Schaake","year":"2012","unstructured":"Schaake EE, Kappers I, Codrington HE, Olmos RAV, Teertstra HJ, van Pel R et al (2012) Tumor response and toxicity of neoadjuvant Erlotinib in patients With early-stage non-small-cell lung cancer. J Clin Oncol 30(22):2731\u20138","journal-title":"J Clin Oncol"},{"issue":"2","key":"918_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","volume":"161","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Fu F, Hu H, Wang S, Li Y, Hu H et al (2021) Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: a phase II study. J Thorac Cardiovasc Surg 161(2):434\u201342.e2","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"918_CR36","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1097\/JTO.0b013e3181f38f70","volume":"5","author":"EB Haura","year":"2010","unstructured":"Haura EB, Sommers E, Song L, Chiappori A, Becker A (2010) A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol 5(11):1806\u201314","journal-title":"J Thorac Oncol"},{"issue":"36","key":"918_CR37","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.1200\/JCO.2009.22.3370","volume":"27","author":"H Lara-Guerra","year":"2009","unstructured":"Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N et al (2009) Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 27(36):6229\u201336","journal-title":"J Clin Oncol"},{"issue":"18","key":"918_CR38","doi-asserted-by":"publisher","first-page":"25632","DOI":"10.18632\/oncotarget.8350","volume":"7","author":"AG Sacher","year":"2016","unstructured":"Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z et al (2016) A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget 7(18):25632\u20139","journal-title":"Oncotarget"},{"issue":"1","key":"918_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijrobp.2023.03.042","volume":"117","author":"N Peled","year":"2023","unstructured":"Peled N, Roisman LC, Levison E, Dudnik J, Chernomordikov E, Heching N et al (2023) Neoadjuvant Osimertinib followed by sequential definitive radiation therapy and\/or surgery in stage III epidermal growth factor receptor-mutant non-small cell lung cancer: an open-label, single-arm, phase 2 study. Int J Radiat Oncol Biol Phys 117(1):105\u201314","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"918_CR40","doi-asserted-by":"publisher","first-page":"e2255050","DOI":"10.1001\/jamanetworkopen.2022.55050","volume":"6","author":"X Hou","year":"2023","unstructured":"Hou X, Li M, Wu G, Feng W, Su J, Jiang H et al (2023) Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases: The GAP BRAIN open-label, randomized, multicenter, Phase 3 Study. JAMA Netw Open 6(2):e2255050","journal-title":"JAMA Netw Open"},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"153473542412682","DOI":"10.1177\/15347354241268231","volume":"23","author":"E Kwag","year":"2024","unstructured":"Kwag E, Kim SD, Shin SH, Oak C, Park SJ, Choi JY et al (2024) A randomized, multi-center, open label study to compare the safety and efficacy between afatinib monotherapy and combination therapy with HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations. Integr Cancer Ther 23:15347354241268232","journal-title":"Integr Cancer Ther"},{"issue":"10","key":"918_CR42","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s11655-017-2819-8","volume":"24","author":"X-B Yang","year":"2018","unstructured":"Yang X-B, Chai X-S, Wu W-Y, Long S-Q, Deng H, Pan Z-Q et al (2018) Gefitinib plus Fuzheng Kang\u2019ai formula in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a randomized controlled trial. Chin J Integr Med 24(10):734\u201340","journal-title":"Chin J Integr Med"},{"issue":"4","key":"918_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.24.00533","volume":"43","author":"X Le","year":"2024","unstructured":"Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA et al (2024) A multicenter open-label randomized phase II study of Osimertinib with and without Ramucirumab in tyrosine kinase inhibitor-Na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial). J clin oncol 43(4):403\u2013411","journal-title":"J clin oncol"},{"issue":"4","key":"918_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11523-023-00975-5","volume":"18","author":"CH Chiu","year":"2023","unstructured":"Chiu CH, Lin MC, Wei YF, Chang GC, Su WC, Hsia TC et al (2023) Efficacy and tolerability of ramucirumab plus erlotinib in Taiwanese patients with untreated, epidermal growth factor receptor-mutated, stage IV non-small cell lung cancer in the RELAY study. Target Oncol 18(4):505\u201315","journal-title":"Target Oncol"},{"issue":"1","key":"918_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jtho.2019.10.003","volume":"15","author":"G Scagliotti","year":"2020","unstructured":"Scagliotti G, Moro-Sibilot D, Kollmeier J, Favaretto A, Cho EK, Grosch H et al (2020) A randomized-controlled phase 2 Study of the MET antibody Emibetuzumab in combination with Erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients. J Thorac Oncol 15(1):80\u201390","journal-title":"J Thorac Oncol"},{"issue":"27","key":"918_CR46","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC-H, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or Cisplatin Plus pemetrexed in patients with metastatic lung adenocarcinoma With EGFR mutations. J Clin Oncol 31(27):3327\u201334","journal-title":"J Clin Oncol"},{"issue":"2","key":"918_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213\u201322","journal-title":"Lancet Oncol"},{"issue":"23","key":"918_CR48","doi-asserted-by":"publisher","first-page":"6967","DOI":"10.1158\/1078-0432.CCR-19-0437","volume":"25","author":"L Li","year":"2019","unstructured":"Li L, Jiang L, Wang Y, Zhao Y, Zhang X-J, Wu G et al (2019) Combination of metformin and gefitinib as First-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: a randomized, double-blind phase II trial. Clin Cancer Res 25(23):6967\u201375","journal-title":"Clin Cancer Res"},{"issue":"9","key":"918_CR49","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","volume":"26","author":"YL Wu","year":"2015","unstructured":"Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z et al (2015) First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol\u202f: Off J Eur Soc Med Oncol 26(9):1883\u20139","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"918_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.587849","volume":"10","author":"S Zhao","year":"2020","unstructured":"Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S et al (2020) Efficacy and tolerability of erlotinib 100 mg\/d vs. gefitinib 250 mg\/d in EGFR-mutated advanced non-small cell lung cancer (E100VG250): an open-label, randomized, phase 2 study. Front Oncol 10:587849","journal-title":"Front Oncol"},{"issue":"2","key":"918_CR51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares L, Tan EH, O\u2019Byrne K, Zhang L, Hirsh V, Boyer M et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28(2):270\u20137","journal-title":"Ann Oncol"},{"issue":"2","key":"918_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A et al (2020) Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38(2):115\u201323","journal-title":"J Clin Oncol"},{"issue":"9","key":"918_CR53","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T et al (2018) Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 36(9):841\u20139","journal-title":"J Clin Oncol"},{"issue":"2","key":"918_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u201325","journal-title":"N Engl J Med"},{"issue":"26","key":"918_CR55","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","volume":"41","author":"BC Cho","year":"2023","unstructured":"Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC et al (2023) Lazertinib versus gefitinib as first-line treatment in patients With EGFR-mutated advanced non-small-cell lung cancer: results From LASER301. J Clin Oncol 41(26):4208\u201317","journal-title":"J Clin Oncol"},{"key":"918_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102068","author":"HA Jung","year":"2023","unstructured":"Jung HA, Park S, Lee SH, Ahn JS, Ahn MJ, Sun JM (2023) Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102068","journal-title":"ESMO Open"},{"issue":"2","key":"918_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.lungcan.2006.07.013","volume":"54","author":"W-C Lin","year":"2006","unstructured":"Lin W-C, Chiu C-H, Liou J-L, Chen Y-M, Perng R-P, Tsai C-M (2006) Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 54(2):193\u20139","journal-title":"Lung Cancer"},{"issue":"1","key":"918_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4143\/crt.2020.459","volume":"53","author":"CK Park","year":"2021","unstructured":"Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC (2021) A Phase II trial of osimertinib as the first-line treatment of non-small cell lung cancer harboring activating EGFR mutations in circulating tumor DNA: LiquidLung-O-Cohort 1. Cancer Res Treat 53(1):93\u2013103","journal-title":"Cancer Res Treat"},{"issue":"8","key":"918_CR59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.biopha.2011.04.017","volume":"65","author":"X Chen","year":"2011","unstructured":"Chen X, Li W, Hu X, Geng Y, Wang R, Yin Y et al (2011) Effect of gefitinib challenge to initial treatment with non-small cell lung cancer. Biomed Pharmacother 65(8):542\u20136","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"918_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.bjc.6603393","volume":"95","author":"H Asahina","year":"2006","unstructured":"Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H et al (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95(8):998\u20131004","journal-title":"Br J Cancer"},{"issue":"5","key":"918_CR61","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.19.00931","volume":"38","author":"JH Cho","year":"2020","unstructured":"Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ et al (2020) Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II Trial (KCSG-LU15-09). J Clin Oncol 38(5):488\u201395","journal-title":"J Clin Oncol"},{"issue":"1","key":"918_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/bjc.2013.721","volume":"110","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A et al (2014) First-line gefitinib in caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 110(1):55\u201362","journal-title":"Br J Cancer"},{"issue":"8","key":"918_CR63","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/jjco\/hyr087","volume":"41","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Matsui K, Katakami N, Takeda K, Moriyama A, Iwamoto Y et al (2011) Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan thoracic oncology group study 0402. Jpn J Clin Oncol 41(8):948\u201352","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"918_CR64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","volume":"2","author":"K Park","year":"2016","unstructured":"Park K, Yu C-J, Kim S-W, Lin M-C, Sriuranpong V, Tsai C-M et al (2016) First-Line Erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the aspiration study. JAMA Oncol 2(3):305\u201312","journal-title":"JAMA Oncol"},{"issue":"2","key":"918_CR65","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3816\/CLC.2005.n.028","volume":"7","author":"DR Spigel","year":"2005","unstructured":"Spigel DR, Hainsworth JD, Burkett ER, Burris HA, Yardley DA, Thomas M et al (2005) Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a minnie pearl cancer research network phase II trial. Clin Lung Cancer 7(2):127\u201332","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"918_CR66","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/sj.bjc.6603159","volume":"94","author":"R Suzuki","year":"2006","unstructured":"Suzuki R, Hasegawa Y, Baba K, Saka H, Saito H, Taniguchi H et al (2006) A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer 94(11):1599\u2013603","journal-title":"Br J Cancer"},{"issue":"4","key":"918_CR67","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00280-014-2548-z","volume":"74","author":"K Takahashi","year":"2014","unstructured":"Takahashi K, Saito H, Hasegawa Y, Ando M, Yamamoto M, Kojima E et al (2014) First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan lung study group 0901. Cancer Chemother Pharmacol 74(4):721\u20137","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"918_CR68","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10147-021-02043-2","volume":"27","author":"Y Tsubata","year":"2022","unstructured":"Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M et al (2022) Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol 27(1):112\u201320","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"918_CR69","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1200\/JCO.2005.04.9890","volume":"24","author":"HL West","year":"2006","unstructured":"West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DHM et al (2006) Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest oncology group study S0126. J Clin Oncol 24(12):1807\u201313","journal-title":"J Clin Oncol"},{"key":"918_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2022.06.012","volume":"170","author":"F Zwierenga","year":"2022","unstructured":"Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM et al (2022) High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial. Lung Cancer 170:133\u201340","journal-title":"Lung Cancer"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00918-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:03:13Z","timestamp":1785927793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00918-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00918-7","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"54"}}